Congratulations to Ultromics on EchoGo Amyloidosis®, an FDA-approved AI solution aiding in the early detection of #cardiacamyloidosis. Early detection is vital to improve patient outcomes and we are proud to have contributed to this important innovation. Read the EchoGo Amyloidosis study in European Heart Journal:
📢 New publication! We're proud to share that EchoGo® Amyloidosis, our FDA-cleared AI screening tool, has been published in the European Heart Journal. The breakthrough technology uses only a single apical 4-chamber echocardiographic videoclip to detect cardiac amyloidosis, a condition that's often missed. 🫀 The study shows performance of EchoGo® Amyloidosis, trained at Mayo Clinic & University of Chicago Medicine, and tested across 18 global sites. 📍 Key takeaways: • Trained and tested on 12,505 studies • Validated in 18 global centers on diverse patient populations • Outperformed conventional screening tools • Delivered 85% sensitivity and 93% specificity in detecting CA • Strong performance across all major amyloidosis subtypes • Supports early identification and referral EchoGo® Amyloidosis delivers insights in minutes to help guide confirmatory testing. Early diagnosis is crucial for effective treatment. 📖 Read the publication: https://lnkd.in/ekd9i5X5 📰 Read the press release: https://lnkd.in/eAVkrZmW #cardiology #EchoGo #cardiacamyloidosis #echocardiography #AIinHealthcare #FDAcleared #digitalhealth #Ultromics #EchoGo #EHJ Jeremy Slivnick, Will Hawkes, Patricia Pellikka, MD, Ross Upton, PhD